Xaprila (xaliproden) / Sanofi  >>  Phase 3
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Xaprila (xaliproden) / Sanofi
NCT00272051: XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy

Completed
3
620
Europe
SR57746A
Sanofi
Metastases, Colorectal Neoplasms, Colorectal Carcinoma
 
05/04
NCT00103649: 18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type

Completed
3
1306
US, Canada
xaliproden (SR57746A)
Sanofi
Alzheimer Disease
10/07
10/07
NCT00104013: Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type

Completed
3
1455
US, Europe, RoW
xaliproden (SR57746A)
Sanofi
Alzheimer Disease
11/07
11/07
NCT00305188 / 2005-002570-30: Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.

Completed
3
879
US, Canada, Europe, RoW
Xaliproden (SR57746A), Placebo, Oxaliplatin, 5-Fluorouracil, 5-FU, Leucovorin, LV
Sanofi
Metastases, Colorectal Neoplasms, Colorectal Carcinoma
10/09
10/09

Download Options